APA (7th ed.) Citation

Shitara, K., Van Cutsem, E., Bang, Y., Fuchs, C., Wyrwicz, L., Lee, K., . . . Tabernero, J. (2020). Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA oncology, 6(10), 1571. https://doi.org/10.1001/jamaoncol.2020.3370

Chicago Style (17th ed.) Citation

Shitara, Kohei, et al. "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy Vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial." JAMA Oncology 6, no. 10 (2020): 1571. https://doi.org/10.1001/jamaoncol.2020.3370.

MLA (9th ed.) Citation

Shitara, Kohei, et al. "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy Vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial." JAMA Oncology, vol. 6, no. 10, 2020, p. 1571, https://doi.org/10.1001/jamaoncol.2020.3370.